Jickky Palmae Sarathy

Jickky Palmae Sarathy

Auto-generated profile, based on publicly available information

Jickky Palmae Sarathy

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
PGPooja Gopal
Pooja Gopal
JSJickky Palmae Sarathy
Jickky Palmae Sarathy
MYMichelle Yee
Michelle Yee
PRPriya Ragunathan
Priya Ragunathan
JSJoon Shin
Joon Shin
Thomas DickThomas Dick
Thomas Dick
Pyrazinamide is a sterilizing first-line tuberculosis drug. Genetic, metabolomic and biophysical analyses previously demonstrated that pyrazinoic acid, the bioactive form of the prodrug pyrazinamide (PZA), interrupts biosynthesis of coenzyme A in Mycobacterium tuberculosis by binding to aspartate decarboxylase PanD. While most drugs act by inhibiting protein function upon target binding, we find here that pyrazinoic acid is only a weak enzyme inhibitor. We show that binding of pyrazinoic acid to PanD triggers degradation of the protein by the caseinolytic protease ClpC1-ClpP. Thus, the old tuberculosis drug pyrazinamide exerts antibacterial activity by acting as a target degrader, a mechanism of action that has recently emerged as a successful strategy in drug discovery across disease indications. Our findings provide the basis for the rational discovery of next generation PZA.

21 February 2023 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
JSJickky Palmae Sarathy
Jickky Palmae Sarathy
CACourtney C. Aldrich
Courtney C. Aldrich
MGMei-Lin Go
Mei-Lin Go
Thomas DickThomas Dick
Thomas Dick
Novel antibiotics are needed to keep antibiotic resistance at bay and to improve treatment of the many drug-susceptible infections for which current therapies achieve poor cure rates. While revolut...